• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease

The new treatment against post-kala-azar dermal leishmaniasis (PKDL) reduces hospitalization days by over 50%, is child-friendly, and reduces the safety risks associated with long antimonial therapy

Home > Press releases

Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease

The new treatment against post-kala-azar dermal leishmaniasis (PKDL) reduces hospitalization days by over 50%, is child-friendly, and reduces the safety risks associated with long antimonial therapy

Young woman in rural setting
Nairobi, Kenya — 17 Jul 2024

A new treatment for people with post-kala-azar dermal leishmaniasis (PKDL) is safer, shorter, and more effective than the current treatment, according to a clinical trial conducted in Sudan by the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) and the Institute of Endemic Diseases at the University of Khartoum, and whose results were published in PLOS Neglected Tropical Diseases.

PKDL can develop after someone has been treated for visceral leishmaniasis (VL), also known as kala-azar. Most common in Eastern Africa and South Asia, the condition starts with a rash around the mouth and can spread to the arms and upper body, and eventually to the entire body, depending on severity. In Sudan, nearly 20% of VL patients will develop PKDL within six months post-treatment, the highest rate worldwide.

The Phase II trial, testing two treatment arms, began in 2018 in Doka, Sudan, with nearly 90% of participants being 12 years or younger. Arm 1 received a combination of oral miltefosine and injectable paromomycin (MF+PM) for 42 days. However, they only needed to stay in the hospital for 14 days during the PM treatment while starting the oral miltefosine simultaneously with the injectable. After leaving the hospital, they continued with the oral treatment at home. At the 12-month follow-up visit, 98% of the participants had achieved a complete cure, including those with moderate and mild PKDL. Arm 2 received a regimen of miltefosine and injectable liposomal amphotericin B (MF+LAmB) for 28 days, staying in the hospital for only 7 days until the LAmB treatment ended and continuing the oral treatment at home after hospital discharge. This group had an 80% cure rate, with MF+LAmB proving to be a good treatment alternative.

Currently, the standard treatment for PKDL is sodium stibogluconate (SSG), an injectable drug given for a lengthy 60-90 days that carries life-threatening toxicity when used for an extended period and requires hospital admission as it must be administered under close supervision.

‘Treatment for PKDL in Sudan is currently only recommended for patients with severe or persistent disease, mainly because SSG is prolonged, toxic, and expensive,’ said Professor Ahmed Musa, Senior Investigator for Leishmaniasis from the Institute of Endemic Diseases, University of Khartoum. ‘But we have now found a safer and better treatment option where patients only need to be admitted to hospital for 14 days and then complete the oral treatment at home. This makes it more patient-friendly, which is important since most people affected by this terrible disease are children.’

Detecting and treating PKDL is also crucial for eliminating VL as a public health problem, the World Health Organization (WHO) has stressed. People treated for PKDL can help prevent new cases since the sandflies that transmit VL get infected when they feed on PKDL lesions. One of the targets in the recently launched VL elimination framework for Eastern Africa is to ensure that all PKDL cases are detected, reported, and managed by 2030. The results of the clinical trial led in Sudan therefore support VL elimination efforts in the region.

‘For a long time, patients with PKDL in Eastern Africa have been left behind by medical research because the disease is not considered life-threatening. Many have had to endure not only stigma but expensive, lengthy treatments exposing them to toxicity,’ said Dr Fabiana Alves, Director of the Leishmaniasis Cluster at DNDi. ‘But this new, shorter, and better treatment will improve the lives of these neglected patients and also help reduce VL transmission on our road to elimination.’

The results of this study will provide evidence to policy makers to guide recommendations of new and more patient-friendly treatments, allowing people with PKDL to benefit from these findings.

Financial support for this study was provided by the World Health Organization – Special Programme for Research and Training in Tropical Diseases (WHO-TDR); the French Development Agency (AFD); Médecins Sans Frontières; the UK International Development; and the Swiss Agency for Development and Cooperation (SDC).

The Science Explained

Download

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected people. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, mycetoma, dengue, paediatric HIV, advanced HIV disease, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health, gender equity and gender-responsive R&D, and diseases impacted by climate change. Since its creation in 2003, DNDi has joined with public and private partners across the globe to deliver 13 new treatments, saving millions of lives.

Media contacts

Paul Barasa (in Nairobi)
Mobile: +254 719 703 195
E-mail: pbarasa@dndi.org

Frédéric Ojardias (in Geneva)
Mobile: +41 79 431 62 16
E-mail: fojardias@dndi.org

Photo credit: Sydelle Willow Smith-EDCTP

Children Clinical trials Stigma Visceral leishmaniasis Sudan

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License